Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
OMP-52M51 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| OMP-52M51 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| OMP-52M51 | DRUG | - |
Inclusion Criteria: Subjects must meet all of the following criteria to be eligible for the study: 1. Age \>18 years 2. ECOG performance status \<2 (see Appendix B) 3. Solid tumor malignancy for which there is no remaining standard therapy or either refuse or are not considered to be candidates fo...
OMP-52M51 is an investigational small molecule being studied for the treatment of relapsed or refractory lymphoid malignancies and relapsed or refractory solid tumors. It is currently in Phase 1 clinical development and is not approved by the FDA.
OMP-52M51 is being developed by Mereo BioPharma Group plc, a biopharmaceutical company traded on the NASDAQ under the ticker symbol MREO. The drug is currently in Phase 1 clinical trials for the treatment of certain cancers.
OMP-52M51 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. Two Phase 1 dose escalation studies have been completed, one in lymphoid malignancies and one in solid tumors.
OMP-52M51 has been studied in two completed Phase 1 clinical trials. NCT01703572 was a dose escalation study in subjects with relapsed or refractory lymphoid malignancies, enrolling 24 participants. NCT01778439 was a dose escalation study in subjects with relapsed or refractory solid tumors, enrolling 48 participants.
No alternative names for OMP-52M51 have been disclosed. The drug is identified solely by its code name OMP-52M51 in clinical trial registries and is being developed by Mereo BioPharma Group plc.